4/A: Allurion Technologies CEO Receives Corrected Stock Option Grant

Shantanu Gaur, CEO of Allurion Technologies, received a corrected stock option grant for 1,428,571 shares, vesting over four years, as detailed in an amended SEC Form 4/A filing.

Summary

• This is an amended SEC Form 4/A filing regarding a stock option grant to Shantanu Gaur, the CEO of Allurion Technologies, Inc.
• The original filing was made on May 7, 2024, and this amendment corrects the number of shares underlying the option.
• The corrected filing shows that Gaur was granted a stock option to purchase 1,428,571 shares of Allurion Technologies common stock at an exercise price of $2.30 per share on May 3, 2024.
• 25% of the shares will vest on May 3, 2025, and the remaining shares will vest in 36 equal monthly installments thereafter, contingent upon Gaur's continued service.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing related to executive compensation. It is neither particularly positive nor negative, but indicates ongoing alignment of management with shareholder interests.

Positives

• The stock option grant aligns the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the technology and healthcare industries to incentivize executives and align their interests with those of shareholders. The size and vesting schedule of the grant are typical for a CEO of a company of Allurion's size and stage.

Comparison to Industry Standards

• Stock option grants for CEOs in similar-sized companies in the medical device industry typically range from 0.5% to 2% of outstanding shares.
• Vesting schedules are commonly structured over 3-4 years to encourage long-term commitment.
• Comparable companies like ResMed or Insulet often use similar equity-based compensation strategies.

Key Dates